Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Boston University and GSK collaborate to tackle pulmonary fibrosis

Boston University and GSK collaborate to tackle pulmonary fibrosis

Anti-fibrotic drug shows promise in breast cancer

Anti-fibrotic drug shows promise in breast cancer

New study offers hope for extending ovarian healthspan and function

New study offers hope for extending ovarian healthspan and function

Shorter leukocyte telomere length and greater LTL attrition tied to cystic fibrosis severity

Shorter leukocyte telomere length and greater LTL attrition tied to cystic fibrosis severity

Insilico Medicine unveils Science42:DORA to streamline academic writing and research

Insilico Medicine unveils Science42:DORA to streamline academic writing and research

Cordyceps sinensis shown to alleviate idiopathic pulmonary fibrosis in mice

Cordyceps sinensis shown to alleviate idiopathic pulmonary fibrosis in mice

Insilico Medicine's PandaOmics Box enhances drug discovery with advanced AI capabilities

Insilico Medicine's PandaOmics Box enhances drug discovery with advanced AI capabilities

Research shows the ability of proteins to predict onset of many diverse diseases

Research shows the ability of proteins to predict onset of many diverse diseases

Senolytic drugs are not a "one-size-fits-all" remedy and may benefit some older women

Senolytic drugs are not a "one-size-fits-all" remedy and may benefit some older women

Insilico Medicine leadership team shares insights on AI-powered healthcare innovation

Insilico Medicine leadership team shares insights on AI-powered healthcare innovation

Family's rare telomere mutation reveals new insights into telomere flexibility and disease

Family's rare telomere mutation reveals new insights into telomere flexibility and disease

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Insilico and NVIDIA unveil new LLM transformer for solving biological and chemical tasks

Insilico and NVIDIA unveil new LLM transformer for solving biological and chemical tasks

COVID-19 linked to rise in autoimmune lung disease, study finds

COVID-19 linked to rise in autoimmune lung disease, study finds

Research shows the impact of social deprivation and distance on pulmonary fibrosis survival

Research shows the impact of social deprivation and distance on pulmonary fibrosis survival

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval

U-M study reveals potential pathway to reverse lung fibrosis

U-M study reveals potential pathway to reverse lung fibrosis

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.